Article Text

Download PDFPDF
Letter
Brain structural alterations in patients with GCH1 mutations associated DOPA-responsive dystonia

Statistics from Altmetric.com

Footnotes

  • Contributors VSK: design and conceptualisation of study; interpretation of data; drafting and revising the manuscript for intellectual content; obtaining funding. FA: design and conceptualisation of study; interpretation of data; revising the manuscript for intellectual content. AT: acquisition, analysis and interpretation of data; revising the manuscript for intellectual content. ES: analysis and interpretation of data; revising the manuscript for intellectual content. NK: acquisition, analysis and interpretation of data; revising the manuscript for intellectual content. SB: analysis and interpretation of data; revising the manuscript for intellectual content. MS: acquisition, analysis and interpretation of data; revising the manuscript for intellectual content. MC: statistical analysis and interpretation of data; revising the manuscript for intellectual content. MF: design and conceptualisation of study; interpretation of data; revising the manuscript for intellectual content; obtaining funding.

  • Funding Ministry of Education, Science, and Technological Development of the Republic of Serbia (project #175090).

  • Competing interests VSK has received speaker honoraria from Roche and Alkaloid; and receives research supports from the Swiss Pharm and Serbian Ministry of Education, Science and Development and Serbian Academy of Sciences and Art. FA is Section Editor of NeuroImage: Clinical; has received speaker honoraria from Philips, Novartis and Biogen Idec; and receives or has received research supports from the Italian Ministry of Health, AriSLA (Fondazione Italiana di Ricerca per la SLA), and the European Research Council. MF is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.